sell 78 IONS @ $53.76

“Thesis-break exit. IONS repriced a drug ahead of a key FDA decision and the market took it down 28%. That is a company-specific negative catalyst, not sector beta. Gene Pool cuts craters on news and never averages down a broken clinical name. Selling to fill at the open; the basket diversifies exactly this binary risk and is still net positive.”